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SUMMARY 19 
 20 
Lactic acid bacteria (LAB) might offer opportunities as oral probiotics provided candidate 21 
strains would persist in the mouth. After intake of a mixture of 69 LAB, especially strains of 22 
Lactobacillus fermentum and L. salivarius were recovered. Co-aggregation with other 23 
microbes is likely not a prerequisite for persistence since L. salivarius strongly co-24 
aggregated with typical oral cavity isolates whereas L. fermentum failed to display this 25 
phenotype. 26 
 3
Certain strains of lactic acid bacteria (LAB) are of interest as probiotics, which are defined as 27 
“live microorganisms that when administered in adequate amounts confer a health benefit on 28 
the host” (7). For oral health applications, despite broad interest of the scientific and 29 
industrial communities (2, 4, 17), functional criteria for selection of probiotics are in their 30 
infancy, and correlations between in vitro data and human intervention studies are scarce (6, 31 
15). One potential mechanism of an oral probiotic is the inhibition of growth and 32 
maintenance of detrimental resident bacteria in specific oral sites. The screening of lactic 33 
acid bacterial species from oral cavities led to the identification of strains of L. paracasei ssp. 34 
paracasei and L. rhamnosus, which inhibited the growth of oral pathogens in vitro, including 35 
Streptococcus. mutans and Porphyromonas. gingivalis (20). Probiotic effects have also been 36 
demonstrated in vivo. The probiotic S. salivarius K12 is proposed to persist in the oral cavity 37 
where it changes the bacterial community and improves oral malodour parameters (1). 38 
Similar observations have been reported for Weissella cibaria (11).  39 
For strategies to decrease the activity or abundance of the detrimental bacteria, colonization, 40 
or at least temporal persistence of probiotic bacteria is a phenotypic trait, which is highly 41 
likely to be required to achieve a functional health benefit (9, 19). The work presented here 42 
evaluates the competitive persistence of a range of LAB in the human mouth. A total of 69 43 
food-grade, lactic acid bacteria (LAB) strains from the Lactobacillus, Lactococcus and 44 
Streptococcus genera were evaluated for their persistence in vivo in the human oral cavity. 45 
The strains were obtained from the NIZO culture collection as well as public culture 46 
collections (Table 1). Spontaneous rifampicin-resistant mutants were selected upon sub-47 
culturing the wild-type strains in medium containing 10 μg/ml rifampicin and subsequently in 48 
50 μg/ml rifampicin. The growth rates of the rifampicin resistant mutants were similar to wild-49 
type cells in laboratory culture media (data not shown).  50 
The rifampicin-resistant LAB strains were separately cultured overnight in the presence of 50 51 
μg/ml rifampicin, washed, and mixed in a final volume of 30 ml of saline at a concentration of 52 
approximately 2x108 cfu per strain. Ethical approval for human studies was given by the 53 
Commissie Mensgebonden Onderzoek regio Wageningen. Three subjects that were 54 
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previously confirmed to lack rifampicin resistant oral bacteria, held the mixture in their mouth 55 
for 1 minute, gently washing the liquid around their oral cavity, after which the mixture of 56 
bacteria was spit out. Saliva, tongue scrapings, and tooth swaps were collected by the 57 
subject after 5 min, 15 min, 1 h, 4 h, 24 h, 13 d and 28 d after administration. Tongue 58 
scrapers (DA retail B.V., Zwolle, The Netherlands) were rinsed in 5 ml saline, and swabs in 1 59 
ml saline. The subjects did not consume any food, but were allowed to drink water, during 60 
the first 4 h after receiving the oral rinse, and subsequently no dietary or behavioral 61 
restrictions were imposed.  62 
Enumeration of total rifampicin-resistant bacteria was performed on standard media 63 
containing 50 μg/ml rifampicin (Fig 1). The highest numbers of colonies from all three 64 
volunteers were recovered from saliva, ranging from 107 cfu/ml 5 min after rinsing to 105-106 65 
cfu / ml 4 h later. In saliva samples, the numbers of rifampicin-resistant bacteria from subject 66 
2 declined >105-fold within the first 24 hours whereas the colony-recovery in saliva samples 67 
from subjects 1 and 3 only dropped 103 fold. Dental swabs consistently contained lower 68 
amounts of LAB inoculants, and tongue scrapings showed considerable variation among the 69 
subjects. Rifampicin resistant bacteria were still recovered at 13 days after administration in 70 
the saliva from subjects 1 and 3 in concentrations of 5 x 101 and 7 x 103 cfu/ml saliva, and in 71 
subject 3 even after 28 days, indicating that in some individuals one or more of the 72 
administered strains display a very high level of persistence.  73 
From each subject, thirty rifampicin-resistant bacterial isolates were selected on the basis of 74 
colony morphology, type of sample and time point (mostly 24 h after administration) of the 75 
LAB strains. Six isolates were collected at the 13 and 28 d time points. Species identification 76 
was performed using V1-V3 16S rRNA gene sequencing (12) (Supplemental Table 1). Fifty 77 
eight percent of the isolates were identified as being Lactobacillus fermentum while only 78 
12% of the strains in the oral rinse were L. fermentum. Also strains of L. salivarius, and L. 79 
(para)casei were recovered frequently among the isolates.  This result is in agreement with 80 
other studies reporting that these species are commonly found in the normal oral microbiota 81 
(14). Isolates of L. brevis, L. delbrueckii, Lactococcus lactis and S. thermophilus were not 82 
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among the 96 isolates examined, suggesting that they are unable to form persistent 83 
populations in the mouth.   84 
Two discriminative colony-types of L. fermentum were isolated. GTG-5 PCR-identification 85 
(16) showed that these represented L. fermentum NIZO1220 (flat rough-edged colonies) and 86 
NIZO2930 (pink, large colonies) (Figure 2). For L. salivarius, molecular typing according to 87 
GTG-5 PCR was not sufficient. RAPD4 (5’- AAGAGCCCGT-3’), M13 (5’- 88 
GAGGGTGGCGGTTCT-3’) and Box-A1R (5’- CTACGGCAAGGCGACGCTGACG-3’) PCRs 89 
assisted in the partial differentiation of the L. salivarius strains recovered from the subjects 90 
(Figure 3). Six out of the nine L. salivarius oral isolates examined showed RAPD4 PCR 91 
patterns shared among L. salivarius strains NIZO880, NIZO881, and NIZO2938. The 92 
remaining L. salivarius isolates were likely strains NIZO2520 and/or NIZO2943. The diversity 93 
of L. salivarius in the recovered bacterial isolates suggest that L. salivarius strains commonly 94 
persist for extended periods in the oral cavity compared to the other species tested. 95 
 96 
In a second human study, rifampicin resistant L. fermentum NIZO1220 and L. salivarius 97 
NIZO2521 were administered in concentrations of 109 cfu to the oral cavity of 5 subjects and 98 
the persistence of these strains was followed over time similar as described above. 99 
Surprisingly, rifampicin resistant colonies were recovered from the oral cavity of subject 1 100 
prior to receiving the oral rinse. This subject was the same individual as subject number 3 in 101 
the initial oral persistence trial. Identification by 16S rRNA gene sequencing and RAPD-PCR 102 
methodology showed that this individual harbored at least two different strains of rifampicin-103 
resistant L. salivarius which were distinct from strain NIZO2521 (data not shown). A similar 104 
long persistence was reported for Lactobacillus rhamnosus GG that was identified in saliva 105 
from a female subject 5 months after he use of LGG (21). 106 
For at least 24 h after administration, the inoculated strains were found in amounts of 102-107 
105 cfu/ml saliva (Fig. 4). Thereafter, L. fermentum or L. salivarius strains were ranging from 108 
between 10 and 1000 cfu/ml saliva at 2 and 5 days after administration, and returned to 109 
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base-line levels in each of the subjects within 15 days although a high inter-individual 110 
variation was observed. 111 
L. fermentum NIZO1220 and L. salivarius NIZO2521 were individually counted in samples 112 
on basis of colony morphology. Since subject 1 had rifampicin-resistant bacteria in the 113 
mouth prior to taking the oral rinse, this subject was excluded from further analysis at the 114 
group level.  In the majority of samples, L. fermentum NIZO1220 was recovered in 1 to 2 log 115 
higher numbers as compared to L. salivarius NIZO2521, although not always significant 116 
(Figure 5). These findings confirm that L. fermentum NIZO1220 and L. salivarius NIZO2521 117 
are LAB with relatively high persistence capacities in the human oral cavity.  118 
 119 
Previous studies evaluating individual strains have shown variable capacities of LAB to 120 
colonize the human mouth. L. reuteri ATCC 55730 that was associated with an in vivo 121 
reduction of S. mutans (18) disappeared in almost 50% of subjects within 24 h (3).  LGG was 122 
maintained in only 66% of the participating subjects after the first day of discontinuation of its 123 
intake (21). Our study is in line with these observations, since the same strains of the 124 
species L. rhamnosus and L. reuteri were included in our initial collection of strains.  In 125 
contrast, S. salivarius K12 persisted in the human oral cavity for a period of up to two weeks 126 
(1). 127 
Co-aggregation is proposed as a mechanism by which oral bacteria adhere to each other 128 
and as a result may colonize persistently in biofilms in the host oral cavity (13). For example, 129 
the capacity of orally administered Weissella cibaria isolates to inhibit resident oral bacteria 130 
is proposed to be at least partially determined by the capacity of these bacteria to co-131 
aggregate with target strains including F. nucleatum, T. denticola, and P. loescheii (11, 13).  132 
To evaluate whether adherence to other oral bacteria might be a factor influencing the 133 
persistence characteristics of LAB in the mouth, the ability to adhere and co-aggregate with 134 
oral bacteria was investigated for the 2 most persistent strains of L. fermentum and all 6 L. 135 
salivarius strains included in the oral rinse. Co-aggregation capacity of lactic acid bacteria 136 
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was performed with cultured representatives of common oral microorganisms that are 137 
implicated as causative agents of bad breath or caries (Table 2).   138 
L. salivarius NIZO2520, NIZO2521, and NIZO2943 co-aggregated with the majority of the 139 
target strains, with the exception of S. mutans and P. melaninogenica (Table 3). Small 140 
aggregates indicated that L. salivarius NIZO2521 also co-aggregated slightly but significantly 141 
with P. melaninogenica HG73 (Supplemental Figure 1). In comparison, L. fermentum 142 
strains NIZO1220 and NIZO2930 and L. salivarius strains NIZO880, NIZO881 and 143 
NIZO2938 did not co-aggregate with any of the oral strains. Possible explanations for the 144 
persistence of L. fermentum may be the ability to adhere to species that were not tested, or 145 
directly to dental surfaces, e.g. by adhesion to salivary proteins. Indeed, in vitro assays 146 
revealed a considerable degree of variation of adherence of individual bacterial strains to 147 
salivary proteins (10), which indicates that co-aggregation is not the sole mechanism by 148 
which bacteria can persist in the oral cavity. 149 
One important caveat which might prevent the use of Lactobacillus as oral probiotics is that 150 
members of this genus have also been associated with childhood caries because of their 151 
strong acidifying characteristics, although their presence was not sufficient to explain all 152 
cases of caries (8). Therefore, probiotic characteristics of the selected strains should be 153 
carefully monitored in vivo, e.g. for the absence of a contribution to dental decay, and not 154 
only based on in vitro characteristics.   155 
In conclusion, the ability of a bacterial strain to persist in the oral cavity is likely to support 156 
oral-probiotic efficacy. The approach we presented here can serve as an initial step in the 157 
selection of candidate probiotic strains aiming to promote oral health.  L. fermentum and L. 158 
salivarius strains display the best extended oral persistence relative to other LAB. Further 159 
evaluation of these strains should examine their effects on the composition and activity of 160 
the endogenous oral microbiota and should be complemented with determination of the 161 
possible consequences for certain health parameters including exhaled VSC, reduced levels 162 
of S. mutans, or other clinically relevant characteristics.  163 
164 
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Table 1. LAB examined for persistence in the human mouth. The LAB strains were routinely 
grown in preferred laboratory culture media under anaerobic conditions (90% N2, 5% 
H2, and 5% CO2). Streptococci and lactococci were grown in M17 medium (Oxoid, 
Hampshire, UK) supplemented with 1 % lactose (or glucose when mentioned) at 30 
°C and 42 °C, respectively. Lactobacilli were grown in MRS medium (Merck, 
Darmstadt, Germany). at 37 °C. 
 
Species source Alternate origin 
L. acidophilus NIZO867 LMG 7943, DSM 20079 N/A = not known 
L. acidophilus NIZO221 ATCC4357 N/A 
L. acidophilus NIZO222   N/A 
L. acidophilus NIZO223   N/A 
L. acidophilus NIZO225   N/A 
L. acidophilus NIZO229   N/A 
L. acidophilus NIZO267   N/A 
L. brevis NIZO2927 NCIMB 8840 human saliva 
L. brevis NIZO289   cheese 
L. brevis NIZO2019   cheese 
L. brevis NIZO1322 LMG 7944, DSM 20054 human feces 
L. brevis NIZO293   cheese 
L. brevis NIZO2491 pork pickeled sausage
L. bulgaricus 5.2   Campina starter culture 
L. bulgaricus 2.3   Campina starter culture 
L. casei ssp. Casei NIZO2928 NCIMB 8822 human saliva 
L. casei ssp. Casei NIZO2929 NCIMB 8823 human saliva 
L. casei ssp. Casei NIZO637   N/A 
L. casei ssp. Casei NIZO889   N/A 
L. casei ssp. Casei NIZO931   N/A 
L. delbrueckii ssp. lactis  NIZO235 ATCC7830 N/A 
L. delbrueckii ssp. lactis  NIZO2944 DSM 20073   saliva 
L. fermentum  NIZO2930 NCIMB 701751 saliva 
L. fermentum  NIZO2931 NCIMB 700335 human oral strain 
L. fermentum  NIZO2517 LMG 9846 saliva 
L. fermentum  NIZO2932 NCIMB 8828 human saliva 
L. fermentum  NIZO2933 NCIMB 8829 human saliva 
L. fermentum  NIZO2934 NCIMB 8830 human saliva 
L. fermentum  NIZO307 ATCC9338 human oral cavity 
L. fermentum  NIZO1220 LMG11441 N/A 
L. paracasei ssp. paracasei  NIZO2935 NCIMB 700680 oral source 
L. paracasei ssp. paracasei NIZO2936 NCIMB 702713 Child saliva 
L. paracasei ssp. paracasei  NIZO2518 DSM 20020   Child saliva 
L. paracasei ssp. paracasei  NIZO2945 DSM 4905   oral cavity 
L. paracasei ssp. paracasei  NIZO1480 DSM 20244 Milk 
L. paracasei ssp. paracasei  NIZO632   N/A 
L. paracasei ssp. paracasei  NIZO1353 
DSM 5622, 
ATCC25302 N/A 
L. pentosus NIZO2514   bamboo shoot pickled 
L. plantarum  NIZO631 N/A
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L. plantarum NIZO2519 LMG 9212 human saliva 
L. plantarum  NIZO1315   N/A 
L. plantarum  NIZO1699   soakwater of soy beans 
L. plantarum  NIZO1317  DSM 20174, LMG6907 pickeled cabbage 
L. plantarum  NIZO2029   Raw-milk cheese 
L. plantarum  NIZO1843   N/A 
L. plantarum  NIZO2484   pork pickled sour sausage 
L. plantarum  NIZO2260 299v, DSM 9843 human intestine 
L. plantarum  NIZO2500   pork pickled sour sausage 
L. plantarum  NIZO2532   shrimp pickled sausage 
L. plantarum  NIZO1836 
NCIMB 8826, WCFS1, 
LMG9211 human saliva 
L. reuteri*  NIZO2691   
(biogaia product) breast 
milk 
L. rhamnosus* NIZO1665 LGG human origin 
L. salivarius NIZO880   human intestine 
L. salivarius NIZO881   human intestine 
L. salivarius ssp. salivarius NIZO2938 NCIMB 8816 human saliva 
L. salivarius ssp. salivarius  NIZO2521 DSM 20555   Saliva 
L. salivarius ssp. salivarius  NIZO2520 DSM 20554   Saliva 
L. salivarius ssp. salivarius  NIZO2943 DSM 20492  human saliva 
Lactococcus. lactis ssp. 
Cremoris NIZO42   N/A 
Lactococcus lactis ssp. 
Cremoris NIZO47   Starter 
Lactococcus lactis ssp. 
Cremoris NIZO57   N/A 
Lactococcus lactis ssp. 
Cremoris NIZO706   N/A 
Lactococcus lactis ssp. 
Diacetylactis NIZO86   starter  
Lactococcus lactis ssp. Lactis NIZO2051   raw-milk curd 
Lactococcus lactis ssp. Lactis NIZO8 R5 N/A 
Lactococcus lactis ssp. Lactis NIZO14   N/A 
S. thermophilus NIZO133   N/A 
S. thermophilus NIZO2269   N/A 
S. thermophilus NIZO122   raw-milk cheese 
*Included for reference purposes 
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Table 2  Strains of oral bacteria used in this study. Streptoccocus mutans was grown on 
M17 containing 1% glucose at 37 °C. The other strains (Table 2) were grown in BHI medium 
(Merck, Darmstadt, Germany) at 37 °C. 
 
Species Strain ID Source 
Porphyromonas gingivalis HG66 ACTA, Amsterdam 
Porphyromonas endodontalis HG181 ACTA, Amsterdam 
Prevotella intermedia HG110 ACTA, Amsterdam 
Prevotella melaninogenica HG73 ACTA, Amsterdam 
Peptostreptococcus anaerobius HG578 ACTA, Amsterdam 
Fusobacterium nucleatum HG646 ACTA, Amsterdam 
Tannerella forsythia HG1245 ACTA, Amsterdam 
Streptococcus mutans UA 159 ACTA, Amsterdam 
Streptococcus mutans NIZO B1215 NIZO culture collection 
Streptococcus mutans C180-2 ACTA, Amsterdam 
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 Table 3.  Co-aggregation of mixtures of Lactobacillus and oral bacteria.  
 
 L.salivarius L.salivarius L.salivarius 
  NIZO2521 NIZO2520 NIZO2943 
Controla 0b,c 0 0 
F. nucleatum HG646 3 3 3 
P. anaerobius HG578 3 3 3 
P. endodontalis HG181 2 2 2 
P. gingivalis HG66 4 4 4 
P. intermedia HG110 3 3 3 
P. melaninogenica HG73 0 0 0 
S. mutans B1215 0 0 0 
T. forsythia HG1245 4 3 3 
 
a L. salivarius without oral bacteria 
b Data are provided for co-aggregation after 2 h of incubation. These results are consistent 
with the findings observed at 4 h and 24 h (data not shown). 
c Scores are based on visual inspection, using the following scoring criteria (5): 0 = no visible 
aggregates in the cell suspension, 1 = small uniform co-aggregates in suspension, 2 = 
definite co-aggregates easily seen but suspension remained turbid, 3 = large co-aggregates 
which settled rapidly leaving some turbidity in the supernatant fluid, 4 = clear supernatant 
fluid and large co-aggregates which settled immediately. 
224 
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Figure legends  225 
 226 
Figure 1 Total numbers of rifampicin resistant LAB recovered from the oral cavity at different 227 
times during the first 24 hours after administration. The saliva (A), tongue (B) and teeth (C) 228 
of the three subjects (subject 1, diamonds; subject 2, squares; subject 3, triangles) 229 
enumerated independently. Limit of detection was 10 cfu per ml of sample. 230 
Figure 2 Dendrogram and GTG5 PCR fingerprints for comparison of L. fermentum strains 231 
included in the oral rinse and isolates from the oral cavity collected during the 1st persistence 232 
trial. For strains, NIZO numbers are denoted. Isolates are indicated by subject number and 233 
isolate number. 234 
Figure 3. Dendrogram and PCR fingerprints for comparison of L. salivarius  strains included 235 
in the oral rinse and isolates from the oral cavity collected during the 1st persistence trial. The 236 
comparison is based on the combined PCR fingerprints obtained by RAPD4, M13, and BOX-237 
A1R.  238 
Figure 4 Recovered total numbers of rifampicin resistant colonies at different time points in 239 
five subjects (subject 1, closed diamonds; subject 2, closed squares; subject 3, closed 240 
triangles; subject 4, open circles; subject 5, asterix) and two sampling sites were 241 
enumerated independently (A: saliva, and B: tongue scrapings). Limit of detection was 10 242 
cfu per ml of sample. 243 
Figure 5 Relative persistence (cfu/ml) of L. fermentum NIZO1220 (black bars) and L. 244 
salivarius NIZO2521 (dashed bars) in the oral cavity of 4 healthy human subjects (subjects 245 
2-5), as measured in saliva (A) and tongue scrapings (B). No rifampicin bacteria were 246 
recovered from subject 2 to 5 before oral administration of the two candidate probiotic 247 
strains. Subject 1 harbored rifampicin-resistant bacteria before administration, and was 248 
therefore excluded from the analysis. Limit of detection was 10 cfu per ml of sample.  249 
 
 





